Trade Show News

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible...

MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm today announced final results from its randomized Phase 2 GDFATHER-NEO trial, which were presented in a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 and simultaneously published in Nature Medicine. The data showed that Growth Differentiation Factor-15 (GDF-15) blockade with visugromab substantially enhanced the anti-tumor activity of the PD‑1 inhibitor nivolumab in the neoadjuvant treatment of patients with...

NEW YORK--(BUSINESS WIRE)--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company’s Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational, allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with progressive multiple sclerosis (MS). The data represent the first reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS and were presented in a late-breaking oral sess...

SINGAPORE--(BUSINESS WIRE)--On October 8, 2026, Striding AI unveiled its Physical AI solution for retail, including two self-developed robots and a robot management platform, at the 22nd Asia-Pacific Retailers Convention & Exhibition (APRCE 2026). Designed for human-robot collaboration in real-world retail environments, the solution automates carrying, shelf replenishment, inventory checks, and patrols, allowing employees to focus on customer service. Robots can also undertake repetitive ov...

HERZLIYA, Israel--(BUSINESS WIRE)--Cognyte Software Ltd. (NASDAQ: CGNT), a global leader in AI-powered investigative analytics solutions, today announced the company will showcase its intelligence and investigation solutions for law enforcement agencies at IACP 2026. IACP brings together more than 16,000 public safety professionals and law enforcement leaders from over 90 countries around the world. WHAT: Experience law enforcement technology that solves cases faster and strengthens field opera...

MADRID--(BUSINESS WIRE)--Genialis Supermodel shows how biology-first AI can extract meaningful insights from limited patient data, across clinical cohorts or a single patient....

BOSTON & BRISBANE, Australia--(BUSINESS WIRE)--AdvanCell Presents Updated Phase 1 Results on ADVC001 at ESMO 2026 with Encouraging Long-term Data...

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced positive preclinical findings demonstrating that DF-003, its proprietary, first-in-class oral ALPK1 inhibitor, reduced kidney inflammation and fibrosis in experimental models of chronic kidney disease (CKD). The findings were presented at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. The research identifies a previously unrecognized role for primary cilia in linking bacterial pathogen recognitio...

GREEN BAY, Wis.--(BUSINESS WIRE)--Learning looks different from student to student. The environments where it happens should make room for those differences. At EDspaces 2026, October 28-30 at the Kansas City Convention Center in Kansas City, Mo., KI will feature Cogni Seating at Booth #2001, highlighting how the collection was designed to support the diverse needs and behaviors students bring into the classroom. Introduced in 2025, Cogni was developed around the understanding that students hav...

CAMBRIDGE, England--(BUSINESS WIRE)--Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results...